We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Paper Based Urine Test Detects Cancer

By LabMedica International staff writers
Posted on 13 May 2014
A technology that combines synthetic biomarkers with a paper-based urine test can detect colorectal cancer and thrombosis in just a few minutes.

The new technique uses exogenous agents injected into the patient, which bind with tumor proteins. More...
A paper strip test then easily detects the synthetic biomarkers in the patient’s urine and the molecular detection system brings a number of existing technologies together in a novel way.

Scientists at the Massachusetts Institute of Technology (MIT; Cambridge, MA, USA) developed nanoparticles that target diseased tissue, such as a tumor, at which point reporter compounds that had been bound to the nanoparticles are released and cleared into the urine. They designed two synthetic biomarkers, one associated with colorectal cancer and another that was specific to blood clots, a common sign of cardiovascular problems. The team demonstrated their ability to detect these compounds in urine from murine models of these diseases using a paper strip coated with targeted antibodies, a strategy called paper lateral flow assay (LFA).

The investigators focused on one group of signals called matrix metalloproteinases (MMPs), because MMPs function to help cancer cells to metastasize. They printed capture antibodies into four parallel test lines relative to a control line and analyzed urine samples that contained one of the four reporters. Similar to the enzyme-linked immunosorbent assay (ELISA) results obtained previously, only the test lines printed with the cognate capture antibody developed a positive signal, highlighting the LFA’s specificity and the capacity to detect distinct reporters with single spatially encoded paper strips.

Sangeeta Bhatia, MD, PhD, a professor and senior author of the study said, “When we invented this new class of synthetic biomarker, we used a highly specialized instrument to do the analysis. For the developing world, we thought it would be exciting to adapt it instead to a paper test that could be performed on unprocessed samples in a rural setting, without the need for any specialized equipment. The simple readout could even be transmitted to a remote caregiver by a picture on a mobile phone.” The study was published on February 24, 2014, in the Proceedings of the National Academy of Sciences of the United States of America (PNAS).

Related Links:

Massachusetts Institute of Technology



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.